GWS
GILD icon

Greykasell Wealth Strategies’s Gilead Sciences GILD Stock Holding History

Greykasell Wealth Strategies’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
1,622
+122
+8% +$16.1K 0.07% 144
2026
Q1 		$209K Sell
1,500
-351
-19% -$49.2K 0.08% 140
2025
Q4 		$227K Sell
1,851
-209
-10% -$25.4K 0.09% 139
2025
Q3 		$229K Buy
2,060
+532
+35% +$60.5K 0.1% 131
2025
Q2 		$169K Buy
+1,528
New +$163K 0.08% 137

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greykasell Wealth Strategies's GILD Position: Q2 2026 in Review

Greykasell Wealth Strategies increased its Gilead Sciences (GILD) stake by 8.1% in Q2 2026, buying an estimated $16.1K and bringing the position to 1,622 shares worth $205K. The position accounts for 0.07% of the portfolio, ranked #144.

Greykasell Wealth Strategies first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $229K in Q3 2025. 2,293 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Greykasell Wealth Strategies held 1,622 shares of Gilead Sciences worth $205K as of Q2 2026.
  • Greykasell Wealth Strategies bought 122 Gilead Sciences shares in Q2 2026, an estimated $16.1K.
  • Gilead Sciences made up 0.07% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #144 holding.
  • Greykasell Wealth Strategies first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Greykasell Wealth Strategies's Gilead Sciences position peaked at $229K in Q3 2025.
  • 2,293 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.